Gaiger A, Hinterberger W
I. Medizinischen Universitätsklinik Wien.
Wien Med Wochenschr. 1991;141(9-10):195-8.
Chronic myelocytic leukemia is a malignant clonal disorder which, after a chronic phase of about 3 to 4 years, progresses to blastic transformation. The disease is incurable by conventional cytostatic treatment. Once blastic transformation has ensued, survival is limited to weeks or months. Interferon may prolong the chronic phase, but data are controversial. Allogeneic bone marrow transplantation may cure 40 to 70% of patients treated while in chronic phase. Survival is about 20% in advanced disease, depending mainly on age, sex of donor and clinical condition. Allogenic bone marrow transplantation was hitherto restricted to patients having an HLA-identical bone marrow donor. Volunteer bone marrow donor registries now contain about 400,000 registered unrelated healthy donors: The chance of finding an unrelated bone marrow donor is now between 10 and 60%, and the chance will increase when donor registries expand.
慢性粒细胞白血病是一种恶性克隆性疾病,在经历约3至4年的慢性期后,会进展为急变期。传统的细胞抑制治疗无法治愈该疾病。一旦进入急变期,生存期仅为数周或数月。干扰素可能会延长慢性期,但数据存在争议。异基因骨髓移植可治愈40%至70%处于慢性期接受治疗的患者。晚期疾病患者的生存率约为20%,主要取决于供者的年龄、性别和临床状况。迄今为止,异基因骨髓移植仅限于拥有人类白细胞抗原(HLA)匹配骨髓供者的患者。志愿骨髓供者登记处目前约有40万名登记在册的非亲属健康供者:现在找到非亲属骨髓供者的几率在10%至60%之间,随着供者登记处的扩大,这一几率将会增加。